Literature DB >> 27503954

Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization.

Chendi Zhan1, Ruxi Qi1, Guanghong Wei2, Emine Guven-Maiorov3, Ruth Nussinov4, Buyong Ma5.   

Abstract

MyD88 is an essential adaptor protein, which mediates the signaling of the toll-like and interleukin-1 receptors' superfamily. The MyD88 L252P (L265P) mutation has been identified in diffuse large B-cell lymphoma. The identification of this mutation has been a major advance in the diagnosis of patients with aldenstrom macroglobulinemia and related lymphoid neoplasms. Here we used computational methods to characterize the conformational effects of the mutation. Our molecular dynamics simulations revealed that the mutation allosterically quenched the global conformational dynamics of the toll/IL-1R (TIR) domain, and readjusted its salt bridges and dynamic community network. Specifically, the mutation changed the orientation and reduced the fluctuation of α-helix 3, possibly through eliminating/weakening ~8 salt bridges and enhancing the salt bridge D225-K258. Using the energy landscape of the TIR domains of MyD88, we identified two dynamic conformational basins, which correspond to the binding sites used in homo- and hetero-oligomerization, respectively. Our results indicate that the mutation stabilizes the core of the homo-dimer interface of the MyD88-TIR domain, and increases the population of homo-dimer-compatible conformational states in MyD88 family proteins. However, the dampened motion restricts its ability to heterodimerize with other TIR domains, thereby curtailing physiological signaling. In conclusion, the L252P both shifts the landscape toward homo-dimerization and restrains the dynamics of the MyD88-TIR domain, which disfavors its hetero-dimerization with other TIR domains. We further put these observations within the framework of MyD88-mediated cell signaling.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  MyD88; TIR domain; TLR; inflammation; protein dynamics

Mesh:

Substances:

Year:  2016        PMID: 27503954      PMCID: PMC5001137          DOI: 10.1093/protein/gzw033

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  39 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

2.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.

Authors:  Konstantin Arnold; Lorenza Bordoli; Jürgen Kopp; Torsten Schwede
Journal:  Bioinformatics       Date:  2005-11-13       Impact factor: 6.937

3.  HIV-1 Tat Protein Activates both the MyD88 and TRIF Pathways To Induce Tumor Necrosis Factor Alpha and Interleukin-10 in Human Monocytes.

Authors:  Rémi Planès; Nawal Ben Haij; Kaoutar Leghmari; Manutea Serrero; Lbachir BenMohamed; Elmostafa Bahraoui
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

4.  MYD88 L265P somatic mutation in IgM MGUS.

Authors:  Ola Landgren; Louis Staudt
Journal:  N Engl J Med       Date:  2012-12-06       Impact factor: 91.245

Review 5.  Assembly and localization of Toll-like receptor signalling complexes.

Authors:  Nicholas J Gay; Martyn F Symmons; Monique Gangloff; Clare E Bryant
Journal:  Nat Rev Immunol       Date:  2014-08       Impact factor: 53.106

6.  MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

Authors:  Lian Xu; Zachary R Hunter; Guang Yang; Yangsheng Zhou; Yang Cao; Xia Liu; Enrica Morra; Alessandra Trojani; Antonino Greco; Luca Arcaini; Marzia Varettoni; Maria Varettoni; Jennifer R Brown; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi; Christopher J Patterson; Robert J Manning; Christina K Tripsas; Neal I Lindeman; Steven P Treon
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

7.  Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.

Authors:  Marzia Varettoni; Luca Arcaini; Silvia Zibellini; Emanuela Boveri; Sara Rattotti; Roberta Riboni; Alessandro Corso; Ester Orlandi; Maurizio Bonfichi; Manuel Gotti; Cristiana Pascutto; Silvia Mangiacavalli; Giorgio Croci; Valeria Fiaccadori; Lucia Morello; Maria Luisa Guerrera; Marco Paulli; Mario Cazzola
Journal:  Blood       Date:  2013-01-25       Impact factor: 22.113

8.  Mutational analysis identifies residues crucial for homodimerization of myeloid differentiation factor 88 (MyD88) and for its function in immune cells.

Authors:  Maria Loiarro; Elisabetta Volpe; Vito Ruggiero; Grazia Gallo; Roberto Furlan; Chiara Maiorino; Luca Battistini; Claudio Sette
Journal:  J Biol Chem       Date:  2013-09-09       Impact factor: 5.157

9.  The SWISS-MODEL Repository and associated resources.

Authors:  Florian Kiefer; Konstantin Arnold; Michael Künzli; Lorenza Bordoli; Torsten Schwede
Journal:  Nucleic Acids Res       Date:  2008-10-18       Impact factor: 16.971

View more
  8 in total

Review 1.  Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.

Authors:  Ryan M Young; James D Phelan; Wyndham H Wilson; Louis M Staudt
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

2.  The Allosteric Effect in Antibody-Antigen Recognition.

Authors:  Jun Zhao; Ruth Nussinov; Buyong Ma
Journal:  Methods Mol Biol       Date:  2021

3.  Pathological mutations differentially affect the self-assembly and polymerisation of the innate immune system signalling adaptor molecule MyD88.

Authors:  Ailís O'Carroll; Brieuc Chauvin; James W P Brown; Ava Meagher; Joanne Coyle; Jurgen Schill; Akshay Bhumkhar; Dominic J B Hunter; Thomas Ve; Bostjan Kobe; Emma Sierecki; Yann Gambin
Journal:  BMC Biol       Date:  2018-12-24       Impact factor: 7.431

4.  Discovery of a Novel MyD88 Inhibitor M20 and Its Protection Against Sepsis-Mediated Acute Lung Injury.

Authors:  Jiali Song; Daoxing Chen; Yingqiao Pan; Xueqin Shi; Qian Liu; Xiaoyao Lu; Ximing Xu; Gaozhi Chen; Yuepiao Cai
Journal:  Front Pharmacol       Date:  2021-11-29       Impact factor: 5.810

5.  Heterologous Expression and Assembly of Human TLR Signaling Components in Saccharomyces cerevisiae.

Authors:  Julia María Coronas-Serna; Elba Del Val; Jonathan C Kagan; María Molina; Víctor J Cid
Journal:  Biomolecules       Date:  2021-11-22

Review 6.  NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy.

Authors:  Paula Grondona; Philip Bucher; Klaus Schulze-Osthoff; Stephan Hailfinger; Anja Schmitt
Journal:  Biomedicines       Date:  2018-03-26

Review 7.  Does Ras Activate Raf and PI3K Allosterically?

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

8.  MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis.

Authors:  Xinfang Yu; Wei Li; Qipan Deng; Haidan Liu; Xu Wang; Hui Hu; Ya Cao; Zijun Y Xu-Monette; Ling Li; Mingzhi Zhang; Zhongxin Lu; Ken H Young; Yong Li
Journal:  Blood       Date:  2021-03-25       Impact factor: 22.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.